Ellipses' next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by US Food and Drug Administration

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Ellipses-Pharma

More Like This

PR Newswire associated0

Ellipses' next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2

Ellipses EP0031/A400 granted Orphan Drug Designation from the US Food and Drug Administration

Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323

Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer

Luoxin Pharmaceutical's LX-039 (Innovative Anti-Tumor Drug): Phase I Clinical Study Data Presented at ESMO 2023

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

PR Newswire associated0

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023